Valuation dashboard for Insulet Corp. (PODD) with P/E 28.71, P/B 7.48, EV/EBITDA 16.8 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin ma...
What would it be worth at its usual multiples?
Versus its usual multiples: fairly priced · Current P/E 28.7× · Multiples range: $164.19 · $164.19.
At its sector median (30.7×) $164 (+7 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Insulet Corp. reported revenue of $2.71B in the most recent fiscal year, growing at a 5-year CAGR of 24.5%. Net income reached $247.1M, with a 105.2% 5-year CAGR.
Trailing-twelve-month margins: gross margin 71.1%, operating margin 16.9%, net margin 12.3%.
At $153.61 (closing price, November 2, 2026), PODD trades at a P/E of 28.71 and an ROE of 26.69%. Market capitalisation stands at $10.7B, placing it among large-cap names.
Balance sheet quality for PODD: debt-to-equity ratio of 0.67, current ratio of 2.48 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 28.71 |
| Price / Book | 7.48 |
| EV / EBITDA | 16.8 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PODD | Insulet Corp. | $10.7B | 28.71 | 7.48 | 26.7% |
| DXCM | DexCom, Inc. | $31.6B | 33.24 | 12.53 | 36.5% |
| ABT | Abbott Laboratories | $190.6B | 40.80 | 3.75 | 9.1% |
| MDT | Medtronic Plc | $127.0B | 24.46 | 2.53 | 10.6% |
| 0Y6X.L | Medtronic Plc | $124.4B | 23.33 | 2.43 | 10.6% |
| SYK | Stryker Corporation | $117.7B | 32.67 | 5.00 | 15.6% |
| 0R2S.L | Stryker Corporation | $111.1B | 31.57 | 4.91 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.7B | 18.42 | 2.71 | 14.9% |
Price
| Price | $153.61 (closing price, November 2, 2026) |
| Market Cap | $10.7B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 26.69% |
| Return on Invested Capital | 16.04% |
| Return on Assets | 11.86% |
| Gross Margin | 71.08% |
| Operating Margin | 16.89% |
| Net Margin | 12.29% |
Related companies: DXCM · ABT · MDT · 0Y6X.L · SYK · 0R2S.L · 0HOY.L · BSX
Explore sector: Healthcare · Medical - Devices
More sections of PODD: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks